Jones P H
Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030.
Am J Med. 1992 Aug;93(2):187-98. doi: 10.1016/0002-9343(92)90050-l.
The strong epidemiologic relationship between specific lipoprotein levels (such as elevated low-density lipoprotein cholesterol or decreased high-density lipoprotein cholesterol) and the future development of coronary heart disease has been well documented. Within the past several years, landmark clinical trials have clearly demonstrated that the incidence of coronary heart disease events is reduced when lipoprotein abnormalities are corrected via pharmacologic therapy. These findings have prompted clinicians to become more vigilant with regard to recognition of dyslipidemias and institution of treatment. This review focuses on the more common primary and secondary dyslipidemias and the currently available lipid-lowering therapies for each disorder. Results of recent coronary angiographic trials are discussed, and implications for the medical management of established coronary heart disease are assessed.
特定脂蛋白水平（如低密度脂蛋白胆固醇升高或高密度脂蛋白胆固醇降低）与冠心病未来发展之间强大的流行病学关系已有充分记录。在过去几年中，具有里程碑意义的临床试验清楚地表明，通过药物治疗纠正脂蛋白异常时，冠心病事件的发生率会降低。这些发现促使临床医生在识别血脂异常和启动治疗方面更加警惕。本综述重点关注更常见的原发性和继发性血脂异常以及针对每种疾病目前可用的降脂疗法。讨论了近期冠状动脉造影试验的结果，并评估了对已确诊冠心病药物治疗的影响。
